Clinical trial
A 26 week, randomized, double-blind, parallel-group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma-related events during treatment with Symbicort�, a fixed combination of inhaled corticosteroid (ICS) (bud
To evaluate the risk of serious asthma related events during treatment with Symbicort pMDI or budesonide pMDI alone (asthma-related deaths, intubations, hospitalizations).
| Category | Value |
|---|---|
| Study start date | 2013-01-08 |